Literature DB >> 31185327

Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: Initial report of reconstruction outcomes and predictors of complications.

Na L Smith1, Krishan R Jethwa1, Jason K Viehman2, William S Harmsen2, Karthik Gonuguntla1, Sarah M Elswick3, Jennifer N Grauberger4, Adam C Amundson1, Thomas J Whitaker1, Nicholas B Remmes1, Christin A Harless3, Judy C Boughey5, Minh-Doan T Nguyen3, Sean S Park1, Kimberly S Corbin1, Robert W Mutter6.   

Abstract

PURPOSE: To report reconstructive outcomes of patients treated with post-mastectomy intensity modulated proton therapy (IMPT) following immediate breast reconstruction (IBR).
MATERIALS AND METHODS: Consecutive women with breast cancer who underwent implant-based IBR and post-mastectomy IMPT were included. Clinical characteristics, dosimetry, and acute toxicity were collected prospectively and reconstruction complications retrospectively.
RESULTS: Fifty-one women were treated between 2015 and 2017. Forty-two had bilateral reconstruction with unilateral IMPT. The non-irradiated contralateral breasts served as controls. Conventional fractionation (median 50 Gy/25 fractions) was administered in 37 (73%) and hypofractionation (median 40.5 Gy/15 fractions) in 14 (27%) patients. Median mean heart, ipsilateral lung V20Gy, and CTV-IMN V95% were 0.6 Gy, 13.9%, and 97.4%. Maximal acute dermatitis grade was 1 in 32 (63%), 2 in 17 (33%), and 3 in 2 (4%) patients. Surgical site infection (hazard ratio [HR] 13.19, 95% confidence interval [CI] 1.67-104.03, p = 0.0012), and unplanned surgical intervention (HR 9.86, 95% CI 1.24-78.67, p = 0.0068) were more common in irradiated breasts. Eight of 51 irradiated breasts and 2 of 42 non-irradiated breasts had reconstruction failure (HR 3.59, 95% CI 0.78-16.41, p = 0.084). Among irradiated breasts, hypofractionation was significantly associated with reconstruction failure (HR 4.99, 95% CI 1.24-20.05, p = 0.024), as was older patient age (HR 1.14, 95% CI 1.05-1.24, p = 0.002).
CONCLUSIONS: IMPT following IBR spared underlying organs and had low rates of acute toxicity. Reconstruction complications are more common in irradiated breasts, and reconstructive outcomes appear comparable with photon literature. Hypofractionation was associated with higher reconstruction failure rates. Further investigation of optimal dose-fractionation after IBR is needed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Complications; Post-mastectomy; Protons; Radiotherapy; Reconstruction

Mesh:

Year:  2019        PMID: 31185327     DOI: 10.1016/j.radonc.2019.05.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer.

Authors:  Robert W Mutter
Journal:  Radiother Oncol       Date:  2019-08-23       Impact factor: 6.280

2.  Risk Factors for Postoperative Complications Following Aesthetic Breast Surgery: A Retrospective Cohort Study of 4973 Patients in China.

Authors:  Lingya Zhang; Jinlong Zheng; Jingpeng Mu; Yunqian Gao; Gehong Li
Journal:  Aesthetic Plast Surg       Date:  2022-08-03       Impact factor: 2.708

Review 3.  The Role of Hypofractionation in Proton Therapy.

Authors:  Alexandre Santos; Scott Penfold; Peter Gorayski; Hien Le
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

4.  Intensity Modulated Proton Therapy for Bilateral Breast or Chest Wall and Comprehensive Nodal Irradiation for Synchronous Bilateral Breast Cancer: Initial Clinical Experience and Dosimetric Comparison.

Authors:  Allison E Garda; Ashley E Hunzeker; Ann K Michel; Sayeh Fattahi; Satomi Shiraishi; Nicholas B Remmes; Heather L Schultz; W Scott Harmsen; Dean A Shumway; Elizabeth S Yan; Sean S Park; Robert W Mutter; Kimberly S Corbin
Journal:  Adv Radiat Oncol       Date:  2022-01-24

Review 5.  Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.

Authors:  Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-14       Impact factor: 7.038

6.  Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy.

Authors:  Line Bjerregaard Stick; Ebbe Laugaard Lorenzen; Esben Svitzer Yates; Carmel Anandadas; Karen Andersen; Cynthia Aristei; Orla Byrne; Sandra Hol; Ingelise Jensen; Anna M Kirby; Youlia M Kirova; Livia Marrazzo; Angela Matías-Pérez; Mette Marie Bruun Nielsen; Henrik Dahl Nissen; Sileida Oliveros; Karolien Verhoeven; Johan Vikström; Birgitte Vrou Offersen
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-04

Review 7.  Personalization in Modern Radiation Oncology: Methods, Results and Pitfalls. Personalized Interventions and Breast Cancer.

Authors:  Cynthia Aristei; Elisabetta Perrucci; Emanuele Alì; Fabio Marazzi; Valeria Masiello; Simonetta Saldi; Gianluca Ingrosso
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

8.  The Impact of Adjuvant Radiotherapy on Immediate Implant-based Breast Reconstruction Surgical and Satisfaction Outcomes: A Systematic Review and Meta-analysis.

Authors:  Ania Zugasti; Bernardo Hontanilla
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-11-05

Review 9.  Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Authors:  Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-25       Impact factor: 8.013

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.